UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OIVID APPROVAL							
OMB Number:	3235-0287						
Estimated average bur	den						
hours per response	0.5						

longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * KASTEN BERNARD L (Last) (First) (Middle) C/O ENZO BIOCHEM, INC., 527 MADISON AVENUE				2. Issuer Name and Ticker or Trading Symbol ENZO BIOCHEM INC [ENZ] 3. Date of Earliest Transaction (Month/Day/Year) 06/02/2011							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _X_Director _Officer (give title below) _Other (specify below)					
(Street) NEW YORK, NY 10022				4. If Amendment, Date Original Filed(Month/Day/Year)						_X_	6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting PersonForm filed by More than One Reporting Person					
(City)		(State)	(Zip)			Ta	ble I	- Non-De	rivativ	e Securitie	s Acquired	Disposed	of, or Bene	ficially Owned		
(Instr. 3) Date		2. Transaction Date (Month/Day/Year)	Execution any	A. Deemed secution Date, i y Month/Day/Year			saction 8)	4. Securities Acqu (A) or Disposed c (Instr. 3, 4 and 5)		f (D) Own Tran	5. Amount of Securities Ben Owned Following Reported Transaction(s) (Instr. 3 and 4)		Ov Fo Di or	wnership orm: Be irect (D) Ov Indirect (In	Nature f Indirect eneficial wnership nstr. 4)	
							Cod	e V	Amou	(A) or (D)	Price			(I (I	nstr. 4)	
								a curr	ently v	alid OME	control n	umber.	uniess the	form display	'S	
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	se (Month/Day/Year) any (Month/Day/Year)	Code		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable a Expiration Date (Month/Day/Year)			7. Title an of Underly Securities (Instr. 3 ar	derlying Derivative Security		f 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I)	11. Nature of Indirect Beneficial Ownershij (Instr. 4)	
				Code	V	(A)	(D)	Date Exercisa		piration te	Title	Amount or Number of Shares		(Instr. 4)	(Instr. 4)	
Restricted Stock Units (1)	(1)	06/02/2011		A		25,000		(1)	06	/02/2013	Common Stock (1		\$ 0	33,532	D	

Reporting Owners

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
KASTEN BERNARD L C/O ENZO BIOCHEM, INC. 527 MADISON AVENUE NEW YORK, NY 10022	X					

Signatures

/s/ Bernard L. Kasten	06/06/2011
**Signature of Reporting Person	Date

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- The Reporting Person was granted 25,000 Restricted Stock Units as compensation for serving as a director of the Company. Each Restricted Stock Unit consists of a right to the issuance of one share of common stock, par value \$0.01 per share. The Restricted Stock Units will vest in two equal annual installments, beginning on June 2, 2012.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.	
1 octional persons who are to respond to the concedent of information contained in this form are not required to respond unless the form displays a currently valid ONID illumber.	